Notice of Results





RNS Number : 8356N
Oxford Biomedica PLC
25 February 2009
 



 

2009/OB/04

EMBARGOED UNTIL 7.00AM, 25 FEBRUARY 2009

25 FEBRUARY 2009

OXFORD BIOMEDICANOTICE OF FY2008 PRELIMINARY RESULTS

RESULTS DATE: 12 MARCH 2009

Oxford, UK - 25 February 2009: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announces today that it will be releasing its preliminary results for the twelve months ended 31 December 2008 on Thursday, 12 March 2009.

Analyst meeting: An analyst briefing will be held at 09:30 am on Thursday, 12 March 2009 at the offices of Buchanan Communications, 45 Moorfields, London EC2Y 9AE. 

Web cast: Simultaneously to the analyst briefing at 09:30 am, there will be a live audio web cast of the presentation. To connect to the web cast facility, please go to the Company's website: http://www.oxfordbiomedica.co.uk/ approximately 10 minutes (09:20 am) before the start of the briefing. This will also be available for replay shortly after the presentation.

 

-Ends-

For further information, please contact:

Oxford BioMedica plc: 

John Dawson, Chief Executive Officer

Tel: +44 (0)1865 783 000

JPMorgan Cazenove Limited:

James Mitford/ Gina Gibson

Tel: +44 (0)20 7588 2828

City/Financial Enquiries:

Lisa BaderoonMark Court/ Mary-Jane Johnson Buchanan Communications

Tel: +44 (0)20 7466 5000

Scientific/Trade Press Enquiries:

Sue Charles/ Holly Griffiths/ John McIntyre

College Hill Life Sciences

Tel: +44 (0)20 7457 2020

US Enquiries:

Thomas Fechtner

The Trout Group LLC

Tel: (646) 378 2900

Notes to editors

1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in cancer immunotherapy and gene-based therapies. The Company was established in 1995, as a spin-out from Oxford University, and is listed on the London Stock Exchange. The Company has a platform of gene delivery technologies, which are based on highly engineered viral systems, and a broad development pipelineOxford BioMedica's lead product candidates are TroVax®a therapeutic vaccine for multiple solid cancers, in Phase III development in collaboration with sanofi-aventis; and ProSavin®, a novel gene-based treatment for Parkinson's diseasein Phase I/II development. The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field. Oxford BioMedica has collaborations with sanofi-aventis, WyethSigma-Aldrich, MolMed and Virxsys. Technology licensees include Biogen Idec, Merck & Co, GlaxoSmithKline and Pfizer. Further information is available at www.oxfordbiomedica.co.uk


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

NORZGGZZZDRGLZZ